Today: 1 July 2026
Browse Category

NASDAQ:GLTO 7 October 2025 - 10 November 2025

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin therapies for myeloproliferative neoplasms and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. GlobeNewswire Damora’s approach is aimed squarely at mutant calreticulin—a well‑validated genetic driver in segments of essential thrombocythemia and myelofibrosis. Targeting this neoantigen has attracted growing interest as researchers seek more disease‑modifying options beyond today’s largely symptom‑managing therapies. Early clinical work from other groups has already shown that mutCALR‑specific antibodies can inhibit oncogenic signaling without harming normal hematopoiesis, underscoring the potential for the class. PMC
Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

Galecto’s stock made headlines on October 7, 2025 by soaring roughly six-fold in value within hours. In pre-market trading that morning, GLTO was up about 632% at one point Stocktwits Stocktwits. Shares that had closed around $3–4 the prior day suddenly traded in the high teens, hitting over two-year highs Stocktwits Stocktwits. Crucially, no new announcement or fundamental development explained this explosion – “there are no new press releases or SEC filings” to account for the surge, one report noted Tipranks. In other words, the rally appears to have been purely market-driven, likely triggered by momentum buyers or algorithmic traders seizing on the low-priced stock. Such an outsized jump on no news suggests a classic speculative frenzy. Indeed, trading volume spiked to extreme levels. About 42 million GLTO shares traded in pre-market alone Tipranks – an astonishing figure given the stock’s small float. By comparison, Galecto’s average daily volume over the past 3 months was only ~2.13 million shares Tipranks. This means that pre-market traders churned through ~20 times the normal volume before the opening bell. For context, Galecto has only ~1.23 million shares in public float Tipranks. The pre-market turnover was a multiple of the entire float, indicating that
7 October 2025

Stock Market Today

  • ASX 200 trails global indexes in 2026 as key healthcare names dive
    July 1, 2026, 3:42 AM EDT. The ASX 200 barely managed a gain of less than 2.8% for the 2026 financial year, outpaced by major overseas markets. The rise was negative after inflation. US stocks soared, with the S&P 500 up 20.8%, NASDAQ up 28.7%, and Europe's STOXX 600 climbing 19%. Losses for CSL-off 52%-and Cochlear, down almost 60%, weighed on the Australian market. Bank results were mixed; ANZ gained 16% but Commonwealth Bank and NAB lagged. 4D Medical stood out with strong returns while the rest of the market barely moved.
Go toTop